Simultaneous Quantification of 25-Hydroxyvitamin D3 and 24,25-Dihydroxyvitamin D3 in Rats Shows Strong Correlations between Serum and Brain Tissue Levels

Ying Xue,1,2 Xin He,1,2 Huan-De Li,1 Yang Deng,1 Miao Yan,1 Hua-Lin Cai,1 Mi-Mi Tang,1,2 Rui-Li Dang,1,3 and Pei Jiang3

1Institute of Clinical Pharmacy & Pharmacology, Second Xiangya Hospital, Central South University, Changsha 410011, China
2School of Pharmaceutical Sciences, Central South University, Changsha 410011, China
3Department of Pharmacy, Jining First People’s Hospital, Jining Medical University, Jining 272000, China

Correspondence should be addressed to Huan-De Li; lihuande1953@126.com and Pei Jiang; jpoet89@126.com

Received 21 September 2015; Revised 9 November 2015; Accepted 15 November 2015

Academic Editor: Stefan Pilz

Copyright © 2015 Ying Xue et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

While vitamin D3 is recognized as a neuroactive steroid affecting both brain development and function, efficient analytical method in determining vitamin D3 metabolites in the brain tissue is still lacking, and the relationship of vitamin D3 status between serum and brain remains elusive. Therefore, we developed a novel analysis method by using high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) to simultaneously quantify the concentrations of 25-hydroxyvitamin D3 (25(OH)D3) and 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) in the serum and brain of rats fed with different dose of vitamin D3. We further investigated whether variations of serum vitamin D3 metabolites could affect vitamin D3 metabolite levels in the brain. Serum and brain tissue were analyzed by HPLC-MS/MS with electrospray ionization following derivatization with 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD). The method is highly sensitive, specific, and accurate to quantify 25(OH)D3 and 24,25(OH)2D3 in animal brain tissue. Vitamin D3 metabolites in brain tissue were significantly lower in rats fed with a vitamin D deficiency diet than in rats fed with high vitamin D3 diet. There was also a strong correlation of vitamin D3 metabolites in serum and brain. These results indicate that vitamin D3 status in serum affects bioavailability of vitamin D3 metabolites in the brain.

1. Introduction

Vitamin D is implicated in a number of disorders such as cancer, immune function, and cardiovascular disease in addition to its established role in regulation of mineral balance and bone health [1–3]. Emerging research also suggests that vitamin D deficiency may play an important role in diseases of central nervous system (CNS), such as depression, Parkinson’s disease, and epilepsy [4–6]. The ignorance of vitamin D status and profiles in brain tissue leads to a barrier in understanding the pathophysiological roles of vitamin D in CNS. Currently, the metabolism, storage, and functions of vitamin D in brain tissue remain ambiguous due to deficient information on the brain distribution of vitamin D metabolites and the correlation of vitamin D levels between serum and brain.

Vitamin D actually consists of two different compounds, vitamin D3 and vitamin D2. A nutritionally adequate amount of vitamin D3 is usually biosynthesized in the skin upon irradiation of 7-dehydrocholesterol by ultraviolet light, and it is also absorbed from the diet [7]. The serum levels of vitamin D2 (which is derived solely from plant sources) and its metabolites are usually less than one-tenth of those of vitamin D3 and its metabolites [8]. Thus, the quantification of vitamin D3 and its metabolites in serum is widely used as a mean of assessing vitamin D status. Once in circulation, vitamin D3 is converted to 25-hydroxyvitamin D3 (25(OH)D3) in the liver, which is subsequently converted into biologically active 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) in the kidney [7]. The half-life of 1alpha,25(OH)2D3 (only 4–8 h) is shorter compared to the half-life of 25(OH)D3 (2-3 weeks),
and 25(OH)D₃ is the best indicator of vitamin D₃ status because it reflects vitamin D supply by all sources well whereas the levels of 1α,25(OH)₂D₃ are tightly regulated by parameters of mineral metabolism [9]. 25(OH)D₃ is thought to be deactivated via conversion into 24,25(OH)₂D₃ by 25-hydroxyvitamin D 24-hydroxylase [10]. Although only 25(OH)D₃ provide clinically relevant information, the quantitation of 24,25(OH)₂D₃ can provide important information of vitamin D metabolism in a research environment.

Lots of advances have been made towards the analysis of vitamin D₃ metabolites in serum in recent years. Gas chromatography- (GC-) mass spectrometry (MS) has been applied to vitamin D₃ metabolites quantification [11]. However the high temperatures used in GC analyses often result in the formation of pyro and isopropyl isomers of the metabolites and there is a risk of degradation of metabolites, which can be avoided by liquid chromatography- (LC-) MS/MS based methods [12]. Considering that immunoassays also suffer from poor accuracy, poor repeatability, and interference, a national dialogue on the measurement of vitamin D status led by the NIH Office of Dietary Supplements has identified LC-MS/MS methodologies as the preferred approaches [13]. However, the analysis of vitamin D₃ metabolites is still a challenge due to the poor ionization efficiency caused by lacking of ionizable polar groups. Derivatization techniques have been developed to enhance the ionization efficiency of vitamin D₃ metabolites to improve the detection response [14]. The representative Cookson-type reagent, 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) which is commercially available, can quantitatively react with s-cis-diene of vitamin D₃ metabolites and reduce interferences [7, 15].

Since vitamin D signaling plays an indispensable role in brain function and development [4, 16, 17], it is significant to find out whether the vitamin D₃ metabolites levels in brain tissue would change with those in serum when rats were given diet lacking vitamin D₃. Investigations that study vitamin D₃ metabolites levels in brain tissue and serum of rats fed with different vitamin D₃ diet may provide a new insight to better understand the relationship of vitamin D₃ status between peripheral circulation and CNS. However, previous analysis of vitamin D₃ metabolites in serum exhibited low sensitivities [15]. Simpler extraction methods and more sensitive detection methods are, therefore, required. In this work, we studied rats fed with different levels of vitamin D₃ diet. HPLC-MS/MS method was developed for simultaneous analyses of these compounds both in rat serum and brain samples. Data were analyzed to access the correlation of vitamin D₃ metabolites levels in brain tissue and serum for the first time. We further investigated whether levels in brain tissue would synchronously change with the levels in serum of rats fed with different vitamin D₃ diet.

2. Material and Methods

2.1. Chemicals. The water was purified using the 12 VDC RO+DI reagent grade water purification systems from AQUA solutions, Inc. (Jasper, Georgia, USA). HPLC-grade acetonitrile (AcN) and methanol (MeOH) were purchased from Merck KGaA (Darmstadt, Germany) and HPLC-grade formic acid (FA) was from ROE scientific Inc. (St. Newark, DE, USA). The standards of 25(OH)D₃ and 24,25(OH)₂D₃ were purchased from ApexBio Technology LLC (Boston, MA, USA). Deuterated internal standard (IS) d₆-25(OH)D₃ was obtained from Sigma-Aldrich (St. Louis, MO, USA). PTAD obtained from Tokyo Chemical Industry Co. (Tokyo, Japan) was used as derivatization reagent.

2.2. Samples Collection. Six-week-old Sprague-Dawley rats were obtained from the Experimental Animal Center of the Second Xiangya Hospital. The rats were kept in a 12/12 light/dark cycle at ambient temperature (20~22°C) and 3 animals per cage. Rats were randomly assigned into 3 groups (6 in each): low vitamin D₃ (LVD), normal vitamin D₃ (NVD), and high vitamin D₃ (HVD). All animals were fed with diets containing 10000IU/kg (HVD) or 100IU/kg (NVD) or 0IU/kg (LVD) vitamin D₃ (1IU = 40 μg) for 6 weeks. Blood was obtained by venipuncture and then centrifuged at 3000×g for 10 min to separate the serum and blood cells. After sacrifice, brains were removed from the skull on ice. Serum and brains were frozen on dry ice and stored at −80°C until analysis.

2.3. Sample Preparation

2.3.1. Brain Samples. After being finely thawed, 1mL of AcN and 10μL IS solution (containing d₆-25(OH)D₃ 100 ng/mL in AcN) were added to 90 mg of rat brain tissue, and the mixtures were homogenized using a tissue homogenizer avoiding light. After vortex for 5 min, the mixture was centrifuged at 4°C for 10 min at 15000×g. The supernatant (800 μL) was then transferred into another Eppendorf tube and subsequently dried under nitrogen gas. The remaining homogenate from different brain tissues was pooled as QC samples for method validation of brain. For derivatization, 100 μL of PTAD solution (1 mg/mL in AcN) was added to the residue followed by 30 s of vortex and 3 min of centrifugation at 15000 g under 4°C. The mixture was put in the room temperature for overnight reaction avoiding light throughout.

2.3.2. Serum Samples. Sample preparation for rat serum was adapted from published methods for human serum [18]. Briefly, 200 μL serum was added with 600 μL AcN and 10 μL IS solution (containing d₆-25(OH)D₃ 100 ng/mL in AcN). The mixtures were vortex-mixed for 3 min and centrifuged at 4°C for 10 min at 15000×g. A batch of serum was mixed as QC samples for method validation of serum. The supernatant (650 μL) was then transferred into another Eppendorf tube and subsequently dried under nitrogen. 100 μL of PTAD solution (1 mg/mL in AcN) was added to the residue for derivatization. Then the mixtures were mixed, centrifuged, and reacted under room temperature overnight as described above.

2.4. Chromatography and Mass Spectrometry. Separation was performed using a Shimadzu LC-20AD chromatograph (Shimadzu Corporation, Kyoto, Japan). Samples were kept in the autosampler in vials at 4°C, and 5μL samples were injected on the column. The Thermo Accucore C18 column (2.6μm,
USA was kept at 35°C. Aqueous phase A was deionized water containing 0.1% FA as a modifier. Organic phase B was 100% MeOH. Starting gradient conditions were 39% A/61% B from 0 to 1 min, reaching 14% A/86% B at 2 min and maintaining for 5.5 min, then returned to 39% A/61% B at 8 min, and retained 3.5 min for equilibration. The flow rate was set at 0.3 mL/min. For MS/MS analysis, a QTRAP 4000 mass spectrometer was operated in electrospray ionization- (ESI-) positive ion multiple reaction monitoring (MRM) mode with the curtain gas set to 25 psi, ion spear voltage set to 5000 V, source temperature set to 600°C, ion source gas set to 170 psi, ion source gas set to 270 psi, declustering potential set to 80 V, entrance potential set to 10 V, and collision cell exit potential set to 10 V. Other compound specific settings were listed in Table 1.

**Table 1: Mass spectrometry conditions.**

| Analytes          | MRM transition (m/z) | CE (V) | Dwell (ms) |
|-------------------|----------------------|--------|------------|
| 25(OH)D$_3$-PTAD  | 558/298              | 25     | 100        |
| 24,25(OH)$_2$D$_3$-PTAD | 574/298          | 30     | 100        |
| d6-25(OH)D$_3$-PTAD | 564/298            | 25     | 100        |

2.5. Method Validation

2.5.1. Preparation of Standard Curves and Linearity Range. By dissolving the analytes in AcN, stock solutions of 25(OH)D$_3$ (1.0 mg/mL) and 24,25(OH)$_2$D$_3$ (0.2 mg/mL) were prepared, which were then further diluted in AcN to the appropriate concentrations for the preparation of calibration curve. The standard curve was prepared in 100% AcN that were analyzed within the same analytical run. The levels of brain tissue standard curve for 25(OH)D$_3$ were 0.39, 0.98, 3.91, 5.86, 78.13, 195.31, 937.50, and 1250.00 ng/mL and for 24,25(OH)$_2$D$_3$ were 0.47, 0.78, 3.13, 7.81, 62.50, 93.75, 500.00, and 1000.00 ng/mL. The levels of serum standard curve for 25(OH)D$_3$ were 0.10, 0.21, 1.04, 5.21, 52.08, 197.92, 833.33, and 1000.00 ng/mL and for 24,25(OH)$_2$D$_3$ were 0.25, 0.50, 2.08, 7.92, 50.00, 100.00, 200.00, and 333.33 ng/mL. To determine the linear range of the method, eight levels ($n = 3$, at each concentration level) of calibration samples were prepared and analyzed as mentioned above.

2.5.2. Limit of Detection and Quantification. The limit of detection (LOD) and limit of quantification (LOQ) were defined as the peaks that give signal to noise ratios of 3:1 and 10:1, respectively, in triplicate.

2.5.3. Precision and Accuracy. To determine the precision and accuracy, endogenous levels of vitamin D$_3$ metabolites in brain and serum QC samples were analyzed. QC samples were prepared following the same procedure giving low, medium, and high concentrations of analytes. 800 μL supernatants of brain homogenates or 200 μL serum was spiked with 10 μL of the IS solution and 10 μL of specific standard solution to generate calibration levels covering a range of analytes (Table 3), respectively. The intraday precision and accuracy were calculated by analyzing QC samples at three concentrations ($n = 5$, at each concentration level) on the same day. The interday precision and accuracy were determined by analyzing the three concentrations in five replicates on three successive days. The precision was calculated as the coefficient of variance (CV) of the intraday and interday analytical results. As reported by previous studies, the accuracy was determined as recovery of each analyte in QC samples at three levels [15, 19]. Accuracy of each analyte was assessed by comparing the difference between QC samples and average levels of mixed blank samples with the added standard.

2.5.4. Matrix Effect. For evaluation of matrix effect (ME), experiments were conducted according to previous work [20, 21]. The spiked samples were prepared by spiking known amounts of standards to 200 μL extracted pooled serum or 800 μL supernatants of brain homogenates. The added concentrations of analytes were the same as the QC samples. And calibrator solutions in AcN with the same levels of standards as the QC samples were also prepared ($n = 5$). The increase in the peak area ratios of the compounds was compared with the respective area ratio measured in calibrator solutions to which the same levels of standards had been added. The matrix effect was calculated as follows:

\[
\text{ME (\%)} = 100 \times \left[ 1 - \frac{\text{peak area ratio in spiked sample} - \text{peak area ratio in pooled sample}}{\text{peak area ratio in calibrator solution}} \right].
\]

2.6. Statistical Analysis. Data acquisition was operated by Analyst 1.6.1 software (AB Sciex). The statistical analysis of the method validation results including calculation of mean, standard deviation, and coefficient of variance was performed using Microsoft Excel. Linear regression analysis using the least-squares method was used to evaluate the calibration curve of each analyte. Associations between analytes in tissue and serum were assessed using Pearson correlation coefficient. The ratio of brain and blood for analytes was assessed by one-way ANOVA and Dunnett’s post hoc test

with SPSS software (version 18.0). The cut-off for statistical significance was set at $P < 0.05$.

3. Results

3.1. Chromatography and Mass Spectrometry Conditions. According to previous reports, targeted analytes herein produced a much stronger signal in positive mode using the electrospray ion source. Thus, all the vitamin D metabolites were detected under MRM mode. The collision energy was
of 25(OH)D3. No interferences were observed at the retention time. Ficnaticy of the method was determined by AcN added with.

The dwell time established for each mass transition (Table 1). The specificity of the method was determined by AcN added with IS. No interferences were observed at the retention time of 25(OH)D3-PTAD and 24,25(OH)2D3-PTAD (Figure 1). The representative MRM chromatograms for 25(OH)D3-PTAD, 24,25(OH)2D3-PTAD, and d6-25(OH)D3-PTAD in serum and brain tissue homogenates are shown in Figures 2 and 3. Production mass spectra for 25(OH)D3-PTAD and 24,25(OH)2D3-PTAD are shown in Figure 4.

3.2. Linearity, LOQ, Precision, Accuracy, and Matrix Effect. All standard curves showed good linearity both in brain homogenates and in serum. The equations of the standard curves, corresponding linear regression coefficients, and linear ranges were illustrated in Table 2. Since the targeted analytes are endogenous metabolites, the LOQs were determined by standard mixtures. The results of LOQs for each analyte were also illustrated in Table 2.

The data of intraday precision, interday precision, and recovery assays were summarized in Table 3 for all analytes both in brain and in serum. The precision was expressed by CVs ranged from 2.5% to 12.9% for intraday precision and from 1.2% to 3.3% for interday precision. Accuracy was determined by recovery. The values of standard addition accuracies and CVs in the QC samples were also shown in Table 3.

The matrix effect for 25(OH)D3 ranged from −3.1 to −5.3 in serum and ranged from −4.1 to −8.1 in brain. For 24,25(OH)2D3, the matrix effect ranged from −3.2 to −4.3 in serum and ranged from −3.6 to −6.6 in brain. The results suggested insignificant matrix effects in the present method.

3.3. Analysis of Vitamin D3 Metabolites in Both Serum and Brain Tissue. The HPLC-MS/MS method was used for the simultaneous determination of 25(OH)D3 and 24,25(OH)2D3 in rat brain tissue homogenates and serum. The results are summarized in Table 4. Serum levels of 25(OH)D3 and 24,25(OH)2D3 significantly increased from the LVD to the NVD group and were highest in the HVD group. In brain tissue, there was also a similar increase of vitamin D3 metabolites over the groups. Compared to the group of normal vitamin D supplement, there was no statistical difference of the 25(OH)D3 brain/serum ratio in different groups, as well as the 24,25(OH)2D3 brain/serum ratio. The brain and serum ratios of 25(OH)D3/24,25(OH)2D3 of different groups were also analyzed compared to the NVD group, and no statistical difference was found.

3.4. Associations of Analytes in Serum and Brain Tissue. Linear regression was used to analyze the levels of vitamin D3 metabolites between serum and brain tissue. Significant correlations were discovered between 25(OH)D3 and 24,25(OH)2D3 levels in serum (Figure 5(a), $r^2 = 0.8133$). Meanwhile, there were also linear correlations of 25(OH)D3 and 24,25(OH)2D3 levels in brain (Figure 5(b), $r^2 = 0.9848$). Similarly, linear regression analysis also indicated that 25(OH)D3 in serum and brain were highly correlated in the total samples (Figure 5(c), $r^2 = 0.6710$). The levels of 24,25(OH)2D3 in serum and brain were also significantly correlated (Figure 5(d), $r^2 = 0.8219$).

### Table 2: Calibration statistics.

| Analytes     | Regression equation | $r^2$ | Linear range (ng/mL) | LOQ (ng/mL) |
|--------------|---------------------|-------|-----------------------|-------------|
| Serum        |                     |       |                       |             |
| 25(OH)D3     | $y = 0.3841x - 0.0477$ | 0.9981 | 0.10–1000.00           | 0.10        |
| 24,25(OH)2D3 | $y = 0.5848x - 0.4085$ | 0.9992 | 0.25–333.30            | 0.25        |
| Brain        |                     |       |                       |             |
| 25(OH)D3     | $y = 0.9673x$       | 0.9947 | 0.39–1250.00           | 0.10        |
| 24,25(OH)2D3 | $y = 0.861x$        | 0.9979 | 0.47–1000.00           | 0.25        |

### Table 3: Intraday and interday precision and recovery of rat brain homogenates and serum.

| Analytes     | ADD (ng/mL) | Intraday Accuracy % | CV % | Interday Accuracy % | CV % |
|--------------|-------------|---------------------|------|---------------------|------|
| Serum        |             |                     |      |                     |      |
| 25(OH)D3     | 7.5         | 98.1                | 3.5  | 97.4                | 1.5  |
|              | 60.0        | 103.3               | 5.0  | 102.5               | 3.3  |
|              | 120.0       | 93.7                | 4.5  | 92.8                | 1.2  |
|              | 0.5         | 99.3                | 12.9 | 102.5               | 2.7  |
| Brain        |             |                     |      |                     |      |
| 25(OH)D3     | 7.5         | 102.0               | 9.2  | 101.1               | 1.4  |
|              | 113         | 99.3                | 2.5  | 101.8               | 1.3  |
| 24,25(OH)2D3 |             |                     |      |                     |      |
| Serum        | 7.5         | 98.2                | 4.3  | 97.5                | 3.3  |
|              | 10.5        | 99.1                | 5.8  | 100.2               | 1.3  |
|              | 21.0        | 98.0                | 7.1  | 98.0                | 1.9  |
| Brain        |              |                     |      |                     |      |
| 25(OH)D3     | 1.5         | 96.3                | 6.8  | 98.9                | 1.4  |
|              | 3.0         | 96.3                | 4.8  | 98.7                | 1.5  |
Table 4: The levels of targeted analytes and ratio of 25(OH)D₃/24,25(OH)₂D₃ in brain homogenates and serum.

| Analytes | Brain (ng/g) | Serum (ng/mL) | Brain/serum |
|----------|--------------|---------------|-------------|
| 25(OH)D₃ |              |               |             |
| LVD      | 1.01 ± 0.25**| 4.14 ± 0.72**  | 0.26 ± 0.11 |
| NVD      | 4.10 ± 1.16  | 14.61 ± 4.40  | 0.28 ± 0.07 |
| HVD      | 13.34 ± 7.26**| 53.52 ± 8.89**| 0.25 ± 0.13 |
| 24,25(OH)₂D₃ |          |               |             |
| LVD      | 0.46 ± 0.24**| 1.13 ± 0.50**  | 0.44 ± 0.17 |
| NVD      | 2.73 ± 1.68  | 4.37 ± 0.96   | 0.60 ± 0.28 |
| HVD      | 6.84 ± 2.84**| 13.52 ± 5.74**| 0.52 ± 0.08 |
| 25(OH)D₁/24,25(OH)₂D₃ |          |               |             |
| LVD      | 2.64 ± 1.15  | 4.67 ± 2.97   | —           |
| NVD      | 1.80 ± 0.74  | 3.37 ± 0.61   | —           |
| HVD      | 1.99 ± 0.88  | 4.51 ± 1.77   | —           |

Values are expressed as mean ± SD; n = 6 for each group. LVD: low vitamin D₃ group; NVD: normal vitamin D₃ group; HVD: high vitamin D₃ group. **P < 0.01 compared to the NVD group.

Figure 1: The representative MRM chromatograms for blank sample added with IS.
4. Discussion

In this study, we designed a new method for synchronous measuring of 25(OH)D$_3$ and 24,25(OH)$_2$D$_3$ in brain tissue and serum. By using this method, we analyzed vitamin D$_3$ metabolites in rats fed with different vitamin D$_3$ doses. As far as we know, this is the first study showing that vitamin D$_3$ metabolites in brain could be significantly affected by vitamin D$_3$ diet and were strongly correlated with serum levels.

The developed LC-MS/MS method was proved to be highly sensitive, specific, and accurate to quantify the 25(OH)D$_3$ and 24,25(OH)$_2$D$_3$ in animal brain tissue for the first time. The procedure described by Lipkie et al. involved a liquid/liquid extraction step to purify the analytes in rat soft tissues, while no satisfying recovery for 25(OH)D$_3$ was achieved [22]. In our work, we employed a simple sample preparation procedure to attain the highly efficient extraction of vitamin D metabolites. Meanwhile, the use of PTAD, a Cookson-type reagent which can react with conjugated diene system of vitamin D metabolites, resulted in an approximately 100-fold increase in the analytical response. Aronov et al. researched the derivatization rates of 25(OH)D$_3$ with PTAD at room temperature [15]. According to a pseudo-first-order kinetics model, $t_{1/2}$ for 25(OH)D$_3$ is shorter than 1 min. Thus >99% yield of derivatization products was achieved after overnight reaction at room temperature in our method. Furthermore, they also found that an increase in PTAD concentration to over 2 mg/mL led to decreased yield. Thus, 1 mg/mL PTAD was chosen in our work. Recent studies showed that two epimers, 6$S$ and 6$R$, were produced by derivatization with PTAD because the reagent reacted with the s-cis-diene moiety from both the $\alpha$- and the $\beta$-sides, and the ratio of 6$S$/6$R$ was approximately 4:1 [23]. Accordingly, there were two peaks for each compound in the MRM ion chromatograms. In this case, the major peak for the 6$S$-isomer was used for integration and quantification.

Figure 2: The representative MRM chromatograms for 25(OH)D$_3$-PTAD (a), 24,25(OH)$_2$D$_3$-PTAD (b), and d6-25(OH)D$_3$-PTAD (c) of serum.
Figure 3: The representative MRM chromatograms for 25(OH)D$_3$-PTAD (a), 24,25(OH)$_2$D$_3$-PTAD (b), and d6-25(OH)D$_3$-PTAD (c) of brain tissue.

Figure 4: Production mass spectra of 25(OH)D$_3$-PTAD (a) and 24,25(OH)$_2$D$_3$-PTAD (b).
As mentioned above, growing evidence has implicated that deficiency of vitamin D plays an important role in diseases of CNS [24, 25]. Thus, it is essential to find out the relationship between serum vitamin D₃ status and its brain concentration. In this research, we evaluated the correlation of 25(OH)D₃ and 24,25(OH)₂D₃ levels between serum and brain tissue of rats with different vitamin D₃ intake for the first time. The results suggested that 25(OH)D₃ status in brain tissue was highly correlated with 25(OH)D₃ in serum of different groups. After giving rats vitamin D₃ deficiency intake for 6 weeks, 25(OH)D₃ serum levels decreased in parallel to a similar decrease of 25(OH)D₃ in brain tissue, while, in the supplement group, 25(OH)D₃ in brain tissue increased with its level in serum. Specific transport mechanisms have been proposed for the transportation of the circulating vitamin D metabolites to the CNS. In peripheral circulation, the majority of 25(OH)D₃ tightly binds to vitamin D binding protein (DBP), forming vitamin D-DBP-complex [26, 27]. The transportation of vitamin D-DBP-complex is dependent on the molecules Megalin and Cubulin in microvessel endothelial cells of rat cerebral [28]. We speculated that Megalin-dependent transport in the choroid plexus could be important for the correlation between 25(OH)D₃ in brain tissue and serum, and the expression of Megalin may change synchronously with the 25(OH)D₃ status in serum to meet the demands of transportation. Furthermore, we found that the 24,25(OH)₂D₃ concentrations were highly correlated with 25(OH)D₃ in serum in different groups, as well as in brain tissue. The results indicated that the catabolism of 25(OH)D₃ into 24,25(OH)₂D₃ rose with increasing 25(OH)D₃ concentrations, which were consistent with the findings of other investigators [29–31]. It also suggests that 24,25(OH)₂D₃, the most abundant 25(OH)D₃ metabolite, in serum or brain tissue cloud serve as an alternative marker of vitamin D status and measurement of 24,25(OH)₂D₃ may provide clinically useful information pertaining to vitamin D status and supplementation. Meanwhile the determination coefficient for serum and brain 24,25(OH)₂D₃ was 0.8219. The strong correlations demonstrated in our research may provide a potential way to estimate the levels of 25(OH)D₃ and 24,25(OH)₂D₃ in brain tissue from the data of serum concentrations.

Figure 5: Correlation between serum 25(OH)D₃ and serum 24,25(OH)₂D₃ (a), brain 25(OH)D₃ and brain 24,25(OH)₂D₃ (b), serum 25(OH)D₃ and brain 25(OH)D₃ (c), and serum 24,25(OH)₂D₃ and brain 24,25(OH)₂D₃ (d).
5. Conclusion

The current study presented a novel HPLC-MS/MS method for simultaneous quantification of 25(OH)D$_3$ and 24,25(OH)$_2$D$_3$ in serum and brain tissue of rats and proposed strong correlations of 25(OH)D$_3$ and 24,25(OH)$_2$D$_3$ between brain tissue and serum in rats receiving different level of vitamin D$_3$ for the first time. The results indicated that the levels of vitamin D metabolites in serum were closely related to those in brain, which may influence the employment of neural cells to vitamin D. Considering that vitamin D$_3$ plays an important role in brain development, insufficient intake of vitamin D$_3$ may negatively affect the function of CNS. Further research should continue to explore the alteration of vitamin D$_3$ metabolites levels with different durations for vitamin D$_3$ supplementation that may aid the clinicians in adjusting the length of time for vitamin D$_3$ supplement to achieve optimum individual benefit.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Huan-De Li and Pei Jiang were responsible for study concept and design; Ying Xue performed the experiments. Xin He, Yang Deng, Miao Yan, Hua-Lin Cai, Mi-Mi Tang, and Rui-Li Dang took in acquisition of date; Ying Xue analyzed and interpreted the data and drafted the paper; Xin He undertook critical revision of the paper. Ying Xue and Xin He contributed equally to the work.

Acknowledgments

This work was supported by Hunan Provincial Innovation Foundation for Postgraduate (no. CX2013B099) and National Natural Science Foundation of China (no. 81401113).

References

[1] Q. Zhang, B. Kanterewicz, S. Buch et al., "CYP24 inhibition preserves 1α,25-dihydroxyvitamin D$_3$ anti-proliferative signaling in lung cancer cells," Molecular and Cellular Endocrinology, vol. 355, no. 1, pp. 153–161, 2012.

[2] J. L. Nobre, P. C. Lisboa, N. D. S. Lima et al., "Calcium supplementation prevents obesity, hyperleptinaemia and hyperglycaemia in adult rats programmed by early weaning," The British Journal of Nutrition, vol. 107, no. 7, pp. 979–988, 2012.

[3] M. T. Cantorna, J. Zhao, and L. Yang, "Vitamin D, invariant natural killer T-cells and experimental autoimmune disease," Proceedings of the Nutrition Society, vol. 71, no. 1, pp. 62–66, 2012.

[4] M. F. Holick, "Medical progress: vitamin D deficiency," The New England Journal of Medicine, vol. 357, no. 3, pp. 266–281, 2007.

[5] L. M. Sayre, G. Perry, and M. A. Smith, "Oxidative stress and neurotoxicity," Chemical Research in Toxicology, vol. 21, no. 1, pp. 172–188, 2008.

[6] N. J. Groves, J. P. Kesby, D. W. Eyles, J. J. McGrath, A. Mackay-Sim, and T. H. J. Burne, "Adult vitamin D deficiency leads to behavioural and brain neurochemical alterations in C57BL/6J and BALB/c mice," Behavioural Brain Research, vol. 241, no. 1, pp. 120–131, 2013.

[7] T. Higashi, Y. Shibayama, M. Fuji, and K. Shimada, "Liquid chromatography-tandem mass spectrometric method for the determination of salivary 25-hydroxyvitamin D$_3$: a noninvasive tool for the assessment of vitamin D status," Analytical and Bioanalytical Chemistry, vol. 391, no. 1, pp. 229–238, 2008.

[8] S. Stanley, "Nursing’s agenda for health care reform: a call to action for nurses and nursing," Journal of Child and Adolescent Psychiatric Nursing, vol. 5, no. 4, p. 37, 1992.

[9] J. M. W. van den Ouweland, M. Vogeser, and S. Bächer, "Vitamin D and metabolites measurement by tandem mass spectrometry," Reviews in Endocrine and Metabolic Disorders, vol. 14, no. 2, pp. 159–184, 2013.

[10] J. P. Crandall, V. Oram, G. Trandafirescu et al., "Pilot study of resveratrol in older adults with impaired glucose tolerance,” Journals of Gerontology—Series A: Biological Sciences and Medical Sciences, vol. 67, no. 12, pp. 1307–1312, 2012.

[11] M. Ishigai, Y. Ishitani, and K. Kumaki, "Characteristics of mass spectrometric analyses coupled to gas chromatography and liquid chromatography for 22-oxacalcitriol, a vitamin D$_3$ analog, and related compounds," Journal of Chromatography B: Biomedical Sciences and Applications, vol. 704, no. 1–2, pp. 11–17, 1997.

[12] B. Yeung, P. Vouros, and G. S. Reddy, "Characterization of vitamin D$_3$ metabolites using continuous-flow fast atom bombardment tandem mass spectrometry and high-performance liquid chromatography," Journal of Chromatography A, vol. 645, no. 1, pp. 115–123, 1993.

[13] C. T. Sempos, H. W. Vesper, K. W. Phinney, L. M. Thienpont, and P. M. Coates, "Vitamin D status as an international issue: national surveys and the problem of standardization," Scandinavian Journal of Clinical and Laboratory Investigation, vol. 72, no. 243, pp. 32–40, 2012.

[14] T. Higashi and K. Shimada, "Derivatization of neutral steroids to enhance their detection characteristics in liquid chromatography–mass spectrometry," Analytical and Bioanalytical Chemistry, vol. 378, no. 4, pp. 875–882, 2004.

[15] P. A. Aronov, L. M. Hall, K. Dettmer, C. B. Stephensen, and B. D. Hammock, "Metabolic profiling of major vitamin D metabolites using Diels-Alder derivatization and ultra-performance liquid chromatography-tandem mass spectrometry," Analytical and Bioanalytical Chemistry, vol. 391, no. 5, pp. 1917–1930, 2008.

[16] K. V. Q. Luo'ng and L. T. H. Nguyen, "The role of vitamin D in Alzheimer’s disease: possible genetic and cell signaling mechanisms," American Journal of Alzheimer’s Disease and other Dementias, vol. 28, no. 2, pp. 126–136, 2013.

[17] X. Cui, H. Gooch, N. J. Groves et al., "Vitamin D and the brain: key questions for future research," The Journal of Steroid Biochemistry and Molecular Biology, vol. 148, pp. 305–309, 2014.

[18] X. Duan, B. Weinstock-Guttman, H. Wang et al., "Ultrasonic quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry," Analytical Chemistry, vol. 82, no. 6, pp. 2488–2497, 2010.

[19] D. Eyles, C. Anderson, P. Ko et al., "A sensitive LC/MS/MS assay of 25OH vitamin D$_3$ and 25OH vitamin D$_2$ in dried blood spots," Clinica Chimica Acta, vol. 403, no. 1–2, pp. 145–151, 2009.
[20] H.-L. Cai, R.-H. Zhu, and H.-D. Li, “Determination of dansylated monoamine and amino acid neurotransmitters and their metabolites in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry,” *Analytical Biochemistry*, vol. 396, no. 1, pp. 103–111, 2010.

[21] J. Marcos, N. Renau, G. Casals, J. Segura, R. Ventura, and O. J. Pozo, “Investigation of endogenous corticosteroids profiles in human urine based on liquid chromatography tandem mass spectrometry,” *Analytica Chimica Acta*, vol. 812, pp. 92–104, 2014.

[22] T. E. Lipkie, A. Janasch, B. R. Cooper, E. E. Hohman, C. M. Weaver, and M. G. Ferruzzi, “Quantification of vitamin D and 25-hydroxyvitamin D in soft tissues by liquid chromatography-tandem mass spectrometry,” *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, vol. 932, pp. 6–11, 2013.

[23] T. Higashi, D. Awada, and K. Shimada, “Determination of 24,25-dihydroxyvitamin D₃ in human plasma using liquid chromatography-mass spectrometry after derivatization with a Cookson-type reagent,” *Biomedical Chromatography*, vol. 15, no. 2, pp. 133–140, 2001.

[24] D. W. Eyles, T. H. J. Burne, and J. J. McGrath, “Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease,” *Frontiers in Neuroendocrinology*, vol. 34, no. 1, pp. 47–64, 2013.

[25] N. J. Groves, J. J. McGrath, and T. H. J. Burne, “Vitamin D as a neurosteroid affecting the developing and adult brain,” *Annual Review of Nutrition*, vol. 34, pp. 117–141, 2014.

[26] A. Nykjaer, J. C. Fyfe, R. Kozyraki et al., “Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D₃,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 24, pp. 13895–13900, 2001.

[27] A. Nykjaer, D. Dragun, D. Walther et al., “An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D₃,” *Cell*, vol. 96, no. 4, pp. 507–515, 1999.

[28] B. V. Zlokovic, C. L. Martel, E. Matsubara et al., “Glycoprotein 330/megalin: Probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid β at the blood-brain and blood-cerebrospinal fluid barriers,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 9, pp. 4229–4234, 1996.

[29] I. Schoenmakers, F. Ginty, L. M. A. Jarjou et al., “Interrelation of parathyroid hormone and vitamin D metabolites in adolescents from the UK and The Gambia,” *Journal of Steroid Biochemistry and Molecular Biology*, vol. 121, no. 1-2, pp. 217–220, 2010.

[30] L. Aksnes and D. Aarskog, “Plasma concentrations of vitamin D metabolites in puberty: effect of sexual maturation and implications for growth,” *Journal of Clinical Endocrinology and Metabolism*, vol. 55, no. 1, pp. 94–101, 1982.

[31] A. F. Taylor and M. E. Norman, “Vitamin D metabolite levels in normal children,” *Pediatric Research*, vol. 18, no. 9, pp. 886–890, 1984.